(HealthDay News) — Daily oral administration of dimethandrolone undecanoate (DMAU) is well tolerated and is associated with reduced serum testosterone (T) levels into the hypogonadal range, according to a study presented at the annual meeting of The Endocrine Society, held from March 17 to 20 in Chicago.

Arthi Thirumalai, MBBS, from the University of Washington Medical Center in Seattle, and colleagues examined the safety, tolerability, pharmacokinetics, and pharmacodynamics of 28 days of daily dosed oral DMAU in healthy men aged 18 to 50 years. One hundred men were randomized to receive daily oral placebo or DMAU with food in 1 of 3 dose groups (100, 200, and 400 mg) and 1 of 2 formulations (castor oil/benzyl benzoate [C] or powder in capsule [P]); 83 participants completed the study.

The researchers found that reductions in serum T into the hypogonadal range were achieved in all active treatment groups, with no significant between-dose or between-formulation differences. Suppression of follicle stimulating hormone and luteinizing hormone was reported for all subjects in the P400mg group and 12 of 13 subjects in the C400mg group. No significant change was seen in mood. There were no significant between-group differences in sexual function as monitored prospectively by the psychosexual diary.

Continue Reading

“Longer term studies are currently under way to confirm that DMAU taken every day blocks sperm production,” a coauthor said in a statement.

Two authors disclosed financial ties to the pharmaceutical industry.

Related Articles


Dimethandrolone undecanoate shows promise as a male birth control pill. Endocrine Society; March 18, 2018 [news release]